Lawrence D. Mayer

Celator Pharmaceuticals (Canada) — Canada

Materials Science · Physical Sciences

56h-index10.4kcitations168works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nanoparticle-Based Drug Delivery(85), RNA Interference and Gene Delivery(38), Lipid Membrane Structure and Behavior(33), Advanced biosensing and bioanalysis techniques(24), Cancer therapeutics and mechanisms(24)

Publications168 total

Data from Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Data from Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
2023Open Access
Data from Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals
Nanomedicine Nanotechnology Biology and Medicine·2020· 27 citedOpen Access
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
Cancer Chemotherapy and Pharmacology·2019· 19 citedOpen Access
<p>CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties</p>
International Journal of Nanomedicine·2019· 112 citedOpen Access
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML
Leukemia Research·2018· 5 cited
Improving combination cancer therapy: the CombiPlex <sup>®</sup> development platform
Future Oncology·2018· 81 citedOpen Access
Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD
Cancer Research·2017· 6 cited
CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation
Leukemia Research·2016· 25 cited
Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation
Blood·2016· 10 cited
Abstract 287: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes
Cancer Research·2016· 1 cited
Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes
Journal of drug targeting·2016· 27 cited
CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia
Blood·2015· 12 cited
Abstract B34: Coordinated delivery of anticancer drug combinations incorporating molecularly targeted agents provides markedly increased plasma drug exposure, decreased toxicity and increased efficacy in preclinical tumor models
Molecular Cancer Therapeutics·2015· 1 cited
page 1 of 9Next →

Frequent Co-authors

Marcel B. Bally(23), Paul Tardi(12), Pieter R. Cullis(11), Troy O. Harasym(8), Sharon A. Johnstone(7), Natashia Harasym(6), Sheela A. Abraham(5), Dana Masin(5), Katarina Edwards(5), Dawn Waterhouse(4), Thomas D. Madden(4), David Bermudes(4), Michael J. Hope(4), Nancy Dos Santos(4), Linda C.L. Tai(3), Arthur C. Louie(3), Murray S. Webb(3), Göran Karlsson(3), Cheryl McKenzie(3), Barry D. Liboiron(3)